Macromolecular prodrug of 4-aminosalicylic acid for targeted delivery to inflamed colon

Current Drug Discovery Technologies

Volumn 10, Issue 1, 2013, Pages 16-24

  Vadnerkar, Gaurav ^a   Dhaneshwar, Suneela ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

4 Aminosalicylic acid; 4 ASA; Colon targeting; Inflammatory bowel disease; Macromolecular prodrug; cyclodextrin

Indexed keywords

AMINOSALICYLIC ACID; BETA CYCLODEXTRIN; SALAZOSULFAPYRIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HYDROLYSIS; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PH; PRIORITY JOURNAL; RAT; THERAPY EFFECT;

EID: 84875429724     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/1570163811310010004     Document Type: Article

References (32)

1. Dhaneshwar SS, Vadnerkar G. Rational design and development of colon-specific prodrugs .Curr Top Med Chem 2011; 11(18): 2318-45.
2. Campregher C, Gasche C. Aminosalicylates. Best Pract Res Clin Gastroenterol 2011; 25: 535-46.
3. Daniel F, Seksik P, Cacheux W, Jian R, Marteau P. Tolerance of 4- aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis. Inflamm Bowel Dis 2004; 10(3): 258-60.
4. Campieri M, Lanfranchi GA, Bertoni F, et al. A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5- aminosalicylic acid in topical treatment of ulcerative colitis. Digestion 1984; 29: 204-8.
5. Ginsberg AL, Beck LS, McIntosh TM, Nochomovitz LE. Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas a double-blind, placebo-controlled trial. Ann Intern Med 1988; 108(2): 195-9.
6. Uhrich KE. Therapeutic azo-compounds for drug delivery. US Patent 6,602,915, May 08, 2000.
7. Cavallaro G, Licciardi M, Caliceti P, Salmaso S, Giammona G. Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. Eur J Pharm Biopharm 2004; 58: 151-9.
8. Uekama K, Hirayama F. Improvements of drug properties by cyclodextrins. In: Wermuth CG, Ed. The Practice of Medicinal Chemistry; Academic Press: London, 1996; pp 793-825.
9. Gerlóczy A, Fónagy A, Keresztes P, Perlaky L, Szejtli J. Absorption, distribution, excretion and metabolism of orally administered 14C-beta-cyclodextrin in rat. Arzneimittelforschung 1985; 35(7): 1042-7.
10. Antenucci R, Palmer JK. Enzymatic degradation of and - cyclodextrins by bacteroides of the human colon. J Agric Food Chem 1984; 32: 1316-21.
11. Uekama K, Minami K, Hirayama F. 6A-O-[(4- biphenylyl)acetyl]-, and cyclodextrins and 6A-deoxy-6A[(4- biphenylyl)acetyl]amino, and -cyclodextrins: potential prodrugs for colon-specific delivery. J Med Chem 1997; 40: 2755-61.
12. Hirayama F, Minami K, Uekama K. In-vitro evaluation of biphenylyl acetic acid-beta-cyclodextrin conjugates as colon-targeting prodrugs: drug release behavior in rat biological media. J Pharm Pharmacol 1996; 48(1): 27-31.
13. Minami K, Hirayama F, Uekama K. Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. J Pharm Sci 1998; 87(6): 715-20.
14. Hirayama F, Ogata T, Yano H, et al. Release characteristics of a short-chain fatty acid, n-butyric acid, from its beta-cyclodextrin ester conjugate in rat biological media. J Pharm Sci 2000; 89(11): 1486-95.
15. Yano H, Hirayama F, Arima H, Uekama K. Hydrolysis behavior of prednisolone 21-hemisuccinate/beta-cyclodextrin amide conjugate: involvement of intramolecular catalysis of amide group in drug release. Chem Pharm Bull 2000; 48(8): 1125-8.
16. Yano H, Hirayama F, Arima H, Uekama K. Preparation of prednisolone- appended alpha-, beta- and gamma-cyclodextrins: substitution at secondary hydroxyl groups and in vitro hydrolysis behavior. J Pharm Sci 2001; 90(4): 493-503.
17. Zou M, Okamoto H, Cheng G, et al. Synthesis and properties of polysaccharide prodrugs of 5-aminosalicylic acid as potential colon- specific delivery systems. Eur J Pharm Biopharm 2005; 59(1): 155-60.
18. Zou MJ, Cheng G, Okamoto H, et al. Colon-specific drug delivery systems based on cyclodextrin prodrugs: in vivo evaluation of 5- aminosalicylic acid from its cyclodextrin conjugates. World J Gastroenterol 2005; 11(47): 7457-60.
19. Dhaneshwar SS, Gairola N, Kandpal M, et al. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease. Eur J Med Chem 2009; 44(10): 3922-9.
20. Dhaneshwar SS, Chail M, Patil M, Naqvi S, Vadnerkar G. Colonspecific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats. Eur J Med Chem 2009; 44(1): 131-42.
21. Vadnerkar G, Dhaneshwar SS. Design and development of latentiated strategy for delivery of mesalazine to colon. J Drug Del Sci Tech 2009; 19(5): 321-9.
22. Zou M, Okamoto H, Cheng G, et al. Synthesis and properties of polysaccharide prodrugs of 5-aminosalicylic acid as potential colon- specific delivery systems. Eur J Pharm Biopharm 2005; 59(1): 155-60.
23. Nielsen NM, Bundgaard H. Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. J Med Chem 1989; 32(3): 727-34.
24. Jung YJ, Lee JS, Kim YM. Colon-specific prodrugs of 5- aminosalicylic acid: synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid. J Pharm Sci 2001; 90(11): 1767-75.
25. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterol 1989; 96(3): 795-803.
26. Zingarelli B, Squadrito F, Graziani P, Camerini R, Caputi AP. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions 1993; 39(3-4): 150-6.
27. Hartmann G, Bidlingmaier C, Siegmund B, et al. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 2000; 292(1): 22-30.
28. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterol 1984; 87(6): 1344-50.
29. Rainsford KD, Whitehouse MW. Anti-inflammatory/anti-pyretic salicylic acid esters with low gastric ulcerogenic activity. Agents Actions 1980; 10(5): 451-6.
30. Rainsford KD. A synergistic interaction between aspirin, or other non-steroidal anti-inflammatory drugs, and stress which produces severe gastric mucosal damage in rats and pigs. Inflammation Res 1975; 5(5): 553-8.
31. Dhaneshwar S, Nagpal D, Singh R, Gairola N, Bodhankar S. Mutual azo prodrug of 5-aminosalicylic acid for colon targeted drug delivery: Synthesis, kinetic studies and pharmacological evaluation. Ind J Pharm Sci 2006; 68(2): 171-7.
32. Cioli V, Putzolu S, Rossi V, Scorza Barcellona P, Corradino C. The role of direct tissue contact in the production of gastrointestinal ulcers by anti-inflammatory drugs in rats. Toxicol Appl Pharmacol 1979; 50(2): 283-9.